Cybin (OTCMKTS:CYBN) Trading Down 5.3%

Cybin Inc. (OTCMKTS:CYBN) shares were down 5.3% on Thursday . The stock traded as low as $0.40 and last traded at $0.41. Approximately 5,637,068 shares were traded during mid-day trading, an increase of 5% from the average daily volume of 5,370,952 shares. The stock had previously closed at $0.43.

Cybin Trading Down 5.3 %

The firm has a market capitalization of $167.30 million, a PE ratio of -1.94 and a beta of 0.38. The firm has a 50-day moving average of $0.37 and a two-hundred day moving average of $0.43.

Cybin (OTCMKTS:CYBN) last issued its earnings results on Wednesday, February 14th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.04). Equities research analysts expect that Cybin Inc. will post -0.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CYBN. Penserra Capital Management LLC raised its position in Cybin by 55.8% in the first quarter. Penserra Capital Management LLC now owns 407,309 shares of the company’s stock valued at $223,000 after purchasing an additional 145,929 shares during the period. Jane Street Group LLC raised its position in Cybin by 370.6% in the first quarter. Jane Street Group LLC now owns 74,631 shares of the company’s stock valued at $61,000 after purchasing an additional 58,771 shares during the period. Royal Bank of Canada raised its position in Cybin by 926.4% in the third quarter. Royal Bank of Canada now owns 109,239 shares of the company’s stock valued at $52,000 after purchasing an additional 98,596 shares during the period. Virtu Financial LLC grew its stake in shares of Cybin by 104.0% during the fourth quarter. Virtu Financial LLC now owns 90,467 shares of the company’s stock valued at $27,000 after acquiring an additional 46,129 shares in the last quarter. Finally, Moneta Group Investment Advisors LLC grew its stake in shares of Cybin by 133,816.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 66,405,251 shares of the company’s stock valued at $19,729,000 after acquiring an additional 66,355,664 shares in the last quarter. 2.02% of the stock is owned by hedge funds and other institutional investors.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.